The octanuclear oxidovanadium(V) complex [V8O20(4,4'-(t)Bubpy)4] (1; 4,4'-(t)Bubpy = 4,4'-di-tert-butyl-2,2'-bipyridine) was synthesized in multigram-scale quantities by the reaction of VOSO4 with 4,4'-(t)Bubpy in the presence of sodium benzoate under O2. The reaction of 1 with MeOH under air afforded the tetranuclear oxidovanadium(V) complex [V4O8(OMe)4(4,4'-(t)Bubpy)2] (2) selectively. In contrast, treatment of 1 with EtOH or MeOC2H4OH under air gave the heptanuclear oxidovanadium(V) complexes [V7O17(OR)(4,4'-(t)Bubpy)3] (R = Et (3a), MeOC2H4 (3b)) having an unprecedented neutral V7O17(OR) core. Although 3a and 3b are relatively stable in CH2Cl2, slow diffusion of Et2O into the solution of 3a in CH2Cl2 afforded 1 as yellow crystals. Complex 2 was also converted into 1 by recrystallization from CHCl3-CH2Cl2/Et2O. (1)H and (51)V NMR as well as electrospray ionization mass spectrometry studies of the behavior of 2 in CD2Cl2 suggested the formation of the methoxido analogue of 3 (3c, R = Me), which is considered to be an intermediate species in the conversion of 2 to 1. The present results provide a rare example of interconversion among neutral vanadium(V) oxide cluster complexes by changing the solvent systems.
No takes yet. Share an insight, caveat, or question.
Kodama et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: